EUCTR2013-003585-14-IT进行中（未招募）1 期
Safety, PK/PD, and efficacy of NOX-H94 in dialysis patients with ESA-hyporesponsive anaemia: A randomized, double blind, placebo controlled parallel group study with a single blind cross-over group - SNOXH94C301
OXXON PHARMA AG0 个研究点目标入组 33 人开始时间: 2021年1月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent
- •2. Male or female of non-childbearing potential
- •3. Age 18 to 85 years
- •4. End stage renal disease treated with maintenance haemodialysis since =3 months, 3 times weekly
- •5. Anaemia : Hb 7 to 11 g/dL
- •6. Functional iron deficiency: Transferrin saturation <30%, Ferritin =300 ng/mL.
- •7. ESA hyporesponsiveness with erythropoietin dose =12,000 IU/ week stable for =4 weeks
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 22
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Inability to personally provide written informed consent or to understand and collaborate throughout the study.
- •2. Inability or unwillingness to comply with study restrictions.
- •3. Participation in any clinical research study evaluating an investigational drug or therapy within 30 days from screening visit or prior enrolment in this study.
- •4. Pregnancy or lactation.
- •5. Treatment with darbepoetin or methoxy-polyethylenglycol-epoetin
- •6. Uncontrolled cardiovascular disease, unstable peripheral arterial or cerebrovascular disease, uncontrolled hypertension (systolic blood pressure >180 mm Hg or diastolic blood pressure >100 mm Hg).
- •7. Congestive heart failure: New York Heart Association Class III or IV.
- •8. Unstable angina, myocardial infarction, percutaneous transluminal coronary angioplasty/stents, or coronary artery bypass grafting <3 months prior screening.
- •9. Any other medical conditions requiring a change in treatment within 4 weeks prior to screening or making study participation unadvisable (at
- •the discretion of the investigator).
- •10. History of clinically relevant haemolysis and/or blood loss.
- •11. AST, ALT, or bilirubin =2.0 times the upper limit of normal.
- •12. Known bone marrow fibrosis.
- •13. Treatment with i.v. iron <4 weeks prior to screening or during the screening period or change in erythropoietin dose during last month.
- •14. Any acute or chronic infection, viral or bacterial within 4 weeks prior to screening or during the screening period that, according to investigator's judgement, is considered as systemic infection.
研究者
相似试验
进行中（未招募）
1 期
Safety and Pharmacology of NOX-H94 in renal dialysis patients with ESA resistant anaemiaEUCTR2013-003585-14-DEOXXON Pharma AG32
进行中（未招募）
不适用
Safety and Pharmacology of NOX-H94 in renal dialysis patients with ESA resistant anaemiaErythropoiesis stimulating agents (ESA) hyporesponsive anaemia in renal dialysis patientsMedDRA version: 18.0Level: SOCClassification code 10038359Term: Renal and urinary disordersSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 18.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 18.0Level: LLTClassification code 10058123Term: Renal anaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-003585-14-ATOXXON Pharma AG32
进行中（未招募）
1 期
Safety and Pharmacology of NOX-H94 in renal dialysis patients with ESA resistant anaemiaEUCTR2013-003585-14-GBOXXON Pharma AG32
已完成
1 期
Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis PatientsEnd Stage Renal DiseaseAnemiaNCT02079896TME Pharma AG33
招募中
3 期
Investigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19IRCT20080901001165N51Sina Darou Laboratories Company80